How do I buy Zoetis (ZTS) stock?

Buying Zoetis (ZTS) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "ZTS", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ZTS by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ZTS is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Zoetis (ZTS) Stock

Q: What is the minimum investment for ZTS on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Zoetis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · ZTS

Trade ZTS

Key stats

Market cap: $33.93B
Price / Earnings ratio: 14.1x
EPS (TTM): $6.08
Volume: Loading
52-week high: $132.49
52-week low: $68.77
Dividend yield: 2.58%
Dividend amount (latest): $0.53
EPS vs analyst estimate: +4.9%Q3 FY25 · $1.70 vs $1.62

Source: third-party data provider, as of November 7, 2026

EPS estimate: analyst consensus

Compare with ZTS

Technical indicators

RSI 14: 56.66
MACD 12/26/9: 2.52
EMA 9 of MACD: 2.05
MACD histogram: 0.47
SMA 50: $75.60; Price above SMA 50
EMA 50: $77.44; Price above EMA 50
SMA 200: $92.72; Price below SMA 200
EMA 200: $93.29; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 11 analyst ratings

Strong Sell0

Sell0

Hold5

Buy6

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

11B7B4B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

19B12B6B0

Revenue to Profit

2025

$9.5B

Revenue

$0.0

Cost of revenue

$6.8B

Gross profit

$0.0

Operating expenses

$2.7B

Net income

Earnings

EPS forecast

Actual EPS

$1.70

$1.62

Q3FY25

$1.40

Q4FY25

$1.57

Q1FY26

$1.82

Q2FY26

$1.77

Q3FY26

The market is expecting earnings per share of $1.77 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Zoetis

Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services.

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees14,500

CEOMs. Kristin C. Peck

IPO DateFeb 1, 2013

HeadquartersParsippany, NJ

Key Executives

Name	Title	Year Born
Ms. Kristin C. Peck	CEO & Director	1971
Mr. Wetteny N. Joseph CPA	Special Advisor to the CEO	1972
Mr. James K. Saccaro	Executive VP, CFO & COO	1973
Ms. Roxanne Lagano	Executive VP, General Counsel & Corporate Secretary	1965
Dr. Robert J. Polzer Ph.D.	Scientific Advisor	1969
Mr. Jamie Brannan	Executive VP & Chief Commercial Officer	1973
Mr. Keith Sarbaugh	Executive VP & Chief Digital and Technology Officer	1979
Mr. Steven Frank	Vice President of Investor Relations	—
Ms. Julie A. Fuller	Executive VP, Chief Human Resources Officer & Global Operations	1973
Mr. Abhay U. Nayak	Executive VP & President of U.S. Commercial Operations	1988

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+1.9	+11.1
2022	-14.6	-2.6	-2.1	-7.3	-2.1	+2.9	+4.8	-12.9	-7.0	-0.4	+0.9	-6.4
2023	+12.7	-0.5	-0.7	+4.8	-9.2	+3.7	+10.5	+2.7	-9.6	-9.1	+16.7	+10.2
2024	-4.5	+4.9	-11.3	-4.7	+7.0	+0.6	+4.3	+0.6	+6.4	-8.0	-3.7	-7.9
2025	+5.1	-2.7	-3.4	-3.4	+8.3	-8.0	-8.4	+6.1	-4.3	-1.9	-11.2	-1.1
2026	-0.9	+4.9	-8.3	-2.0	-31.9	-7.3	+6.7	+0.0	-9.6	+15.4	+7.2

Stocks in the same sector

Amneal Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc

ANIP

ANI Pharmaceuticals Inc

FAQ

Buying Zoetis (ZTS) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "ZTS", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ZTS by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Zoetis from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Yes, Zoetis regularly pays dividends to shareholders. Currently, the estimated dividend yield for ZTS is around 2.58% per year. On Gotrade, cash dividends will be automatically credited to your account balance (after taxes).

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Zoetis (ZTS) Stock

Key stats

Compare with ZTS

Recent news

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key Metrics

Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Michael Burry Says S&P 500 Looks ‘Uncannily Close’ To 2000 — And ‘Busted’ Stocks Could Be The Winners

Michael Burry Says S&P 500 Looks ‘Uncannily Close’ To 2000 — And ‘Busted’ Stocks Could Be The Winners

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis Appoints Iris Knobloch to its Board of Directors

Zoetis Appoints Iris Knobloch to its Board of Directors

About Zoetis

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade